- OncoImmune, Inc., a Rockville, Md.-based clinical-stage biopharmaceutical company, completed a $56m Series B equity financing
- The round co-led by HM Capital and a blue-chip investor
- Existing investors, 3E Bioventures Capital and Kaitai Capital, as well as additional new investors, GBA Fund and GF Xinde, also joined the round
- The company will also use the proceeds to support its novel therapeutic programs in late stage clinical trials and to expand its product pipeline
- OncoImmune actively engaged in the discovery and development of novel immunotherapies for cancer, inflammation and autoimmune diseases
- Then the company currently has two Phase III clinical programs to evaluate its lead product CD24Fc
